What Are the Special Properties of MRSA Prodrug TXA709?
AUG 17, 2017 | CONTAGION® EDITORIAL STAFF
Edmond LaVoie, PhD, professor and chair, Department of Medicinal Chemistry, Ernest Mario School of Pharmacy, co-founder of TAXIS Pharmaceuticals, explains how the initial drug discovery process for MRSA drug TX709 evolved. The vision was to develop a drug that could be orally bioavailable, but still have a sustained effect. Dr. LaVoie explains how TXA709 has "necessary properties" that allow for it to be formulated for infusion. TXA709 has proved efficacious by the intravenous and oral routes in animal model studies, which offers significant clinical advantages.
To stay informed on the latest in infectious disease news and developments, please sign upfor our weekly newsletter.
Contagion® is a fully integrated news resource covering all areas of infectious disease. Through our website, quarterly journal, email newsletters, social media outlets, and Outbreak Monitor we provide practitioners and specialists with disease-specific information designed to improve patient outcomes and assist with the identification, diagnosis, treatment, and prevention of infectious diseases. Our mission is to assure that the healthcare community and public have the knowledge to make more informed choices and have a positive impact on patient outcomes.
2 Clarke Drive
Cranbury, NJ 08512